MARKET

VTVT

VTVT

Vtv Therapeutics
NASDAQ
0.8099
-0.0449
-5.25%
Opening 12:18 05/30 EDT
OPEN
0.8300
PREV CLOSE
0.8548
HIGH
0.8303
LOW
0.7904
VOLUME
39.60K
TURNOVER
16.61K
52 WEEK HIGH
1.400
52 WEEK LOW
0.5036
MARKET CAP
84.70M
P/E (TTM)
-3.8366
1D
5D
1M
3M
1Y
5Y
vTv gains 13% on patent win for potential brain tumor pill
Seeking Alpha · 6d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 6d ago
BRIEF-vTv Therapeutics Announces Issuance Of U.S. Patent For Azeliragon As A Treatment Of Glioblastoma To Cantex Pharmaceuticals
Reuters · 6d ago
Cantex Pharmaceuticals Receives US Patent Covering vTv Therapeutics' Azeliragon
Cantex Pharmaceuticals Receives US Patent Covering vTv Therapeutics' Azeliragon
MT Newswires · 6d ago
vTv Therapeutics GAAP EPS of -$0.06 beats by $0.05
Seeking Alpha · 05/11 21:15
BRIEF-Vtv Therapeutics Announces 2023 First Quarter Financial Results And Provides Corporate Update
Reuters · 05/11 21:10
Spending on weight loss drugs to rise 378% in 2023 – 2027: report
Seeking Alpha · 05/07 16:00
Lilly obesity therapy shows ~16% weight loss in Phase 3 trial
Seeking Alpha · 04/27 10:55
More
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes HPP593, Nrf2/Bach1 Modulator Program, Azeliragon and HPP3033.

Webull offers kinds of vTv Therapeutics Inc stock information, including NASDAQ:VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.